Amwise Diagnostic PTE. LTD. Our flagship product, RecurIndex®, is the world's only breast cancer postoperative recurrence risk assessment tool developed based on Chinese genes.

With patented genetic analysis technology and clinical factors, RecurIndex® accurately assesses the risk of breast cancer recurrence and metastasis after surgery. This enables doctors to develop the most suitable treatment strategies for early-stage breast cancer patients, optimizing treatment outcomes while minimizing side effects. Our innovative technology can identify high-risk patients who are truly at risk of recurrence or metastasis, allowing for necessary treatment at an early stage.

Currently, our product is applicable to breast cancer and can be used to assess the necessity of radiotherapy or chemotherapy for patients. Additionally, we have also initiated research on colorectal cancer, aiming to help more cancer patients